{"entity":{"id":"self-amplifying-rna","kind":"technology","name":"Self-amplifying and circular RNA therapeutics","aka":[],"tldr":"RNA drugs that copy themselves inside the cell, or are made as a loop so they last longer. Both aim to get more protein from a smaller dose.","summary":"Self-amplifying RNA carries a replicase, so a small dose produces protein for days; circular RNA has no free ends, resists exonucleases, and is translated for longer than linear mRNA. Both are being applied to cancer vaccines and to in vivo expression of antibodies, cytokines, and CAR constructs. Oncology work is early phase and largely company-reported; the approved precedent is a self-amplifying COVID-19 vaccine, not a cancer therapy.","status":"phase-1","asOf":"2026-09-08","links":[{"label":"ClinicalTrials.gov: self-amplifying RNA cancer","url":"https://clinicaltrials.gov/search?term=self-amplifying%20RNA%20cancer"}],"tags":["frontier","promising"],"related":[],"cancers":[],"sections":["immunotherapy","drug-discovery"],"technologies":["neoantigen-mrna-vaccine","shared-antigen-vaccine","in-vivo-car-t"],"targets":[],"drugs":[],"companies":["biontech","moderna","orna-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"An alphavirus-derived replicase amplifies the transcript in the cytoplasm (saRNA), or a permuted intron-exon strategy circularises the RNA to extend its half-life; both are delivered in lipid nanoparticles.","strengths":["Lower dose for the same protein output","Longer expression than linear mRNA","Shares manufacturing with approved mRNA vaccines"],"limitations":["Innate sensing of double-stranded replication intermediates","Little peer-reviewed oncology efficacy data","Same delivery ceiling as all lipid nanoparticles: the liver takes most of it"]},"route":"/technologies/self-amplifying-rna/","neighbours":{"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/"},{"id":"orna-therapeutics","kind":"company","name":"Orna Therapeutics (Eli Lilly)","route":"/companies/orna-therapeutics/"}],"roadmap":[{"id":"frontier-2035","kind":"roadmap","name":"Radical oncology: what could change the war by 2035","route":"/roadmaps/frontier-2035/"}]}}